Asia Pacific experts uncover gender-based disparity in diagnosis, treatment, and management of Atrial Fibrillation
A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Nov. 17, 2022 /PRNewswire/ -- Biosense Webster, Inc., part of Johnson & Johnson MedTech, today announced the release of a report titled, 'Atrial Fibrillation Exacts Toll on Women: Addressing the Gender Disparity in the Treatment...
[CES 2023] AI FOR PET NAMED AS CES 2023 INNOVATION AWARDS HONOREE
SEOUL, South Korea, Nov. 17, 2022 /PRNewswire/ -- AI FOR PET today announced that it has been named as CES 2023 Innovation Awards Honoree for TTcare. This year's CES Innovation Awards program received a record-high number of over 2100 submissions. The announcement was made ahead of CES 2023, the world's most influential technology event, happening Jan. 5-8 in Las...
Standigm Synthetic Research Center successfully accelerates drug discovery in its first year
Lab uniquely enables collaboration between chemical and AI researchers SEOUL, South Korea, Nov. 17, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced the celebration of its Synthetic Research Center's first year. In the last 12 months, the company has collaborated with outside researchers to create hundreds of novel molecules...
Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA
--While the ASC61 Phase I study is ongoing in the U.S., the Investigational New Drug (IND) approval in China will accelerate the global development of ASC61, an in-house developed oral PD-L1 small molecule inhibitor HANGZHOU and SHAOXING, China, Nov. 17, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the approval of the Investigational New Drug...
RemeGen’s Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines
YANTAI, China, Nov. 17, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a Chinese commercial-stage biotechnology company, announced on November 5 that the Company's self-developed novel antibody-drug conjugate (ADC) Disitamab Vedotin (RC48) has been officially included in the newly released Chinese Society of Clinical Oncology (CSCO) 2022 Guidelines for the Treatment and Management of Urothelial...
See-Mode Technologies Receives Health Canada Approval for AI Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans
MELBOURNE, Australia, Nov. 17, 2022 /PRNewswire/ -- See-Mode Technologies, a MedTech company based in Australia that is on a mission to unlock the hidden insights within medical imaging, today announced that it has received approval from Health Canada for its product expansion to support Breast & Thyroid ultrasound examinations. See-Mode uses Artificial...
SLACOM and NCCN Launch International Project to Improve Breast Cancer Care in Argentina
National Comprehensive Cancer Network and the Latin American and Caribbean Society of Medical Oncology collaborate to address policy and practice solutions to increase equitable access for breast cancer care, starting in Argentina and then expanding more broadly. BUENOS AIRES, Argentina and PLYMOUTH MEETING, Pa., Nov. 16, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network®...
Landmacy Seeks to Expand Growth Amid Rising Demand for Vegan Supplements
NANTOU, Taiwan, Nov. 16, 2022 /PRNewswire/ -- Landmacy Healthcare Tech Company, the Taiwan-based herbal expert for vegan nutraceutical and nutritional supplements whose name combines "land" and "pharmacy," announced that it is seeking opportunities to expand its business to the wider international market, focusing on the US. The company specializes in 100% plant-based, non-GMO, and cruelty-free supplements and holistic remedies....
BDT Capital Partners acquires minority stake in Exyte
Partnership will enhance Exyte's long-term strategy as the world leader in the design, engineering, and delivery of high-tech facilities Exyte serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers; industries offering secular long-term growth Exyte confirms it is successfully on its "Pathway to Ten", targeting...
Lunit to Supply AI Platform to Australia’s BreastScreen NSW Machine Reading Project
Lunit's INSIGHT MMG solution has been selected for mammogram screening in Australia's BreastScreen NSW's AI evaluation and clinical integration project Successful completion of project to be followed by 5-year operation contract with BSNSW to assist radiologists in examining 350,000 women per year SEOUL, South Korea, Nov. 16, 2022 /PRNewswire/ --...
